{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:05:19Z","timestamp":1792292719706,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["2016\/679"],"award-info":[{"award-number":["2016\/679"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["216\/16"],"award-info":[{"award-number":["216\/16"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["26 January2022"],"award-info":[{"award-number":["26 January2022"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004271","name":"Sapienza Universit\u00e0 di Roma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jgar.2022.06.027","type":"journal-article","created":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T17:14:05Z","timestamp":1656868445000},"page":"326-334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Bictegravir\/emtricitabine\/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3406-7014","authenticated-orcid":false,"given":"Daniele","family":"Armenia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Forbici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-2627","authenticated-orcid":false,"given":"Giulia","family":"Berno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Malagnino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6351-2623","authenticated-orcid":false,"given":"Roberta","family":"Gagliardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanni","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Gennari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0754-6917","authenticated-orcid":false,"given":"Stefania","family":"Cicalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Buonomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Teti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Lanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Latini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1452-0333","authenticated-orcid":false,"given":"Loredana","family":"Sarmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo F.","family":"Perno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2022.06.027_sbref0001","series-title":"HIV antiretroviral therapy","author":"Kemnic","year":"2021"},{"key":"10.1016\/j.jgar.2022.06.027_bib0002","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/14740338.2021.1887135","article-title":"Risks and benefits of reducing the number of drugs to treat HIV-1 infection","volume":"20","author":"Cadi\u00f1anos","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jgar.2022.06.027_bib0003","doi-asserted-by":"crossref","DOI":"10.1177\/2325958219867325","article-title":"Optimizing antiretroviral therapy in treatment-experienced patients living with HIV: a critical review of switch and simplification strategies. An opinion of the HIV Practice and Research Network of the American College of Clinical Pharmacy","volume":"18","author":"Chastain","year":"2019","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"10.1016\/j.jgar.2022.06.027_bib0004","unstructured":"DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV developed by the DHHS Panel on Antiretroviral Guidelines for Adults 2022, https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf; [Accessed 28 July 2022]."},{"key":"10.1016\/j.jgar.2022.06.027_bib0005","unstructured":"European AIDS Clinical Society. European AIDS Clinical Society (EACS) Guidelines 10.1 October 2020. Version 10.1. 2020, https:\/\/www.eacsociety.org\/files\/guidelines-10.1_30032021_1.pdf; [Accessed 28 July 2022]."},{"key":"10.1016\/j.jgar.2022.06.027_bib0006","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s40265-018-1010-7","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide: a review in HIV-1 infection","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2022.06.027_bib0007","doi-asserted-by":"crossref","first-page":"e27330","DOI":"10.1097\/MD.0000000000027330","article-title":"Real-world efficacy and safety of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in older people living with","volume":"100","author":"Rolle","year":"2021","journal-title":"HIV. Medicine (Baltimore)"},{"key":"10.1016\/j.jgar.2022.06.027_bib0008","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40121-021-00419-5","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed people with HIV aged \u226565 years: week 48 results of a phase 3b, open-label trial","volume":"10","author":"Maggiolo","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2022.06.027_bib0009","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus","volume":"73","author":"Sax","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.06.027_bib0010","series-title":"Prevalence and risk factors of preexisting TAMs in clinical trial participants and sustained viral suppression after switching to bictegravir\/emtricitabine\/tenofovir alafenamide. 18th EACS 2021","author":"Andreatta","year":"2021"},{"key":"10.1016\/j.jgar.2022.06.027_bib0011","series-title":"Long-term efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide after switch from boosted protease inhibitor-based regimens including in those with pre-existing resistance and viral blips. 18th EACS 2021","author":"Andreatta","year":"2021"},{"key":"10.1016\/j.jgar.2022.06.027_bib0012","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/QAI.0000000000002454","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) from dolutegravir (DTG) +F\/TAF or DTG+F\/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance","volume":"85","author":"Acosta","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2022.06.027_bib0013","series-title":"Efficacy of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in patients with pre-existing NRTI resistances: real world data. 18th EACS 2021","author":"Mic\u00e1n","year":"2021"},{"key":"10.1016\/j.jgar.2022.06.027_bib0014","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/QAI.0000000000002635","article-title":"Prevalence and outcomes for heavily treatment-experienced individuals living with human immunodeficiency virus in a European cohort","volume":"87","author":"Pelchen-Matthews","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2022.06.027_bib0015","series-title":"10th IAS Conf HIV Sci 2019","article-title":"Identifying heavily treatment-experienced patients in a large administrative claims database","author":"Henegar","year":"2019"},{"key":"10.1016\/j.jgar.2022.06.027_bib0016","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1097\/QAD.0000000000002679","article-title":"Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options","volume":"34","author":"Bajema","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2022.06.027_bib0017","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/ciu020","article-title":"Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels","volume":"58","author":"Santoro","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.06.027_bib0018","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/jac\/dkv029","article-title":"HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia","volume":"70","author":"Armenia","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.06.027_bib0019","first-page":"1","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jgar.2022.06.027_bib0020","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.2147\/IDR.S331647","article-title":"Outcomes after switching to BIC\/FTC\/TAF in patients with virological failure to protease inhibitors or non-nucleoside reverse transcriptase inhibitors: a real-world cohort study","volume":"14","author":"Chang","year":"2021","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2022.06.027_bib0021","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/QAI.0000000000002888","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) efficacy in participants with pre-existing primary integrase inhibitor resistance through 48 weeks of phase 3 clinical trials","volume":"89","author":"D'Antoni","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2022.06.027_bib0022","doi-asserted-by":"crossref","first-page":"ofy113","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study","volume":"5","author":"Gagliardini","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2022.06.027_bib0023","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/QAI.0000000000002787","article-title":"Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding","volume":"88","author":"Ciccullo","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2022.06.027_bib0024","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev-genom-091212-153406","article-title":"Deep sequencing of HIV: clinical and research applications","volume":"15","author":"Chabria","year":"2014","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.jgar.2022.06.027_bib0025","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3390\/ijerph15081697","article-title":"Sanger and next generation sequencing approaches to evaluate HIV-1 virus in blood compartments","volume":"15","author":"Arias","year":"2018","journal-title":"Int J Environ Res Public Health"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522001618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522001618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:23:25Z","timestamp":1778858605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716522001618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":25,"alternative-id":["S2213716522001618"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2022.06.027","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bictegravir\/emtricitabine\/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2022.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}